---
figid: PMC8494520__10-1055-a-1475-4335-igf02
figtitle: Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current
  Aspects
organisms:
- Homo sapiens
- Mus musculus
- unidentified
organisms_ner:
- Homo sapiens
- Mus musculus
pmcid: PMC8494520
filename: 10-1055-a-1475-4335-igf02.jpg
figlink: /pmc/articles/PMC8494520/figure/FI14754335en-2/
number: F2
caption: PARPi-mediated tumour cell effects allowing combined treatment with immune
  checkpoint blockade. PARP inhibition (similar to BRCA1/2 loss of function) leads
  to an accumulation of fragmented double-stranded DNA (dsDNA) in the cytosol of the
  tumour cell. This activates the cGAS/STING signalling pathway, which ultimately
  triggers a type I interferon response. This also releases downstream chemokines
  (CXCL10, CXCL11, CCL5), among others, which attract tumour-suppressive T and NK
  cells into the tumour. However, PD-L1 expression is also upregulated in the tumour
  microenvironment. Both immune cell recruitment and PD-L1 induction now permit effective
  immune checkpoint blockade.
papertitle: Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current
  Aspects.
reftext: Holger Bronger. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1128-1144.
year: '2021'
doi: 10.1055/a-1475-4335
journal_title: Geburtshilfe und Frauenheilkunde
journal_nlm_ta: Geburtshilfe Frauenheilkd
publisher_name: Georg Thieme Verlag KG
keywords: ovarian cancer | immune checkpoint blockade | PD-L1 | tumour-infiltrating
  lymphocytes
automl_pathway: 0.9238865
figid_alias: PMC8494520__F2
figtype: Figure
redirect_from: /figures/PMC8494520__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8494520__10-1055-a-1475-4335-igf02.html
  '@type': Dataset
  description: PARPi-mediated tumour cell effects allowing combined treatment with
    immune checkpoint blockade. PARP inhibition (similar to BRCA1/2 loss of function)
    leads to an accumulation of fragmented double-stranded DNA (dsDNA) in the cytosol
    of the tumour cell. This activates the cGAS/STING signalling pathway, which ultimately
    triggers a type I interferon response. This also releases downstream chemokines
    (CXCL10, CXCL11, CCL5), among others, which attract tumour-suppressive T and NK
    cells into the tumour. However, PD-L1 expression is also upregulated in the tumour
    microenvironment. Both immune cell recruitment and PD-L1 induction now permit
    effective immune checkpoint blockade.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - CXCL10
  - CCL5
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - CGAS
  - STING1
  - CD274
  - Parp1
  - Cxcl10
  - Ccl5
  - Cgas
  - Sting1
  - Cd274
---
